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ABSTRACT
Masseter hypertrophy (MH) is rare, asymptomatic condition with unexplained etiology. The main finding 
is unilateral or bilateral benign enlargement of masseter muscles, which results in a pronounced contour of 
the face and/or in the angle of the lower jaw, as well as the occurrence of asymmetry in unilateral hypertro-
phy.
Surgical resection of the masseter was a conventional method in the past for asymmetric edema treatment 
above the shoulder and the angle of the lower jaw, after unsuccessful altering of the vertical dimension, 
dental aligners, tranquilizers, etc. An effective alternative is injecting locally small doses of botulin tox-
in type A in the masseter. The toxin prevents the release of acetylcholine, causing presynaptic neuromuscu-
lar blockage. This way the muscles could be selectively weakened and after local paralysis muscle atrophy is 
observed. This technique ensures predictable result and it is an alternative conservative method for treat-
ing this type facial asymmetry. Another conservative way for treating MH is radio frequency electrocoagu-
lation. The presence of MH after dental treatment requires specialized intervention of specialists and appli-
cation of contemporary non-invasive interventions with predictable results.
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INTRODUCTION
The masseter muscle is one of the four main 
chewing muscles and is essential in the sufficient 
chewing process. М. masseter is located along the 
side of ramus mandibulae and has a square form. 
It consists of a superficial and a deep part. The sur-
face part (pars superficialis) starts from os zygomat-
icum and from the front end of the arcus zygomati-
cus with thick tendon. It continues in the muscle part 
that goes back sidewards and connects to tuberosi-
tas masseterica at angulus mandibulae. The deep part 
of the muscle, pars рrofundа, starts at the inside sur-
face of arcus zygomaticus and fascia temporalis, con-
tinues almost upright under the superficial part and 
connects to the outside surface of ramus mandibulае. 
Both parts are separated at the back through niche, 
filled with connective tissue. М. masseter is the most 
powerful lifter of the lower jaw. Thanks to its ideal fi-
ber path from biomechanical point of view it com-
presses both teeth rows with the help of isomet-
ric curtailment of power, equal to the weight of the 
body. Because of the sideward path of the superficial 
part, the muscle plays a role in the forward move-
ment of the lower jaw as well. Together with m. ptery-
goideus medialis it comprises the muscle loop around 
аngulus mandibulae, in which both muscles work in 
sync, as they make up for about 55 % of the mastica-
tory pressure.
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mus mandibulae and plays an important role in fa-
cial esthetics. A common characteristic in MH is 
the changed contour of the face and this causes dis-
comfort and has negative cosmetic impact on the pa-
tients. This is a reason for more noticeable angle of 
the mandible, changes in facial lines (more square). 
DIAGNOSTIC METHODS 
There are conventional methods of diagnosing 
MH – clinical examination, palpation, photo analy-
sis. Patients complain about pain in the muscles relat-
ed to TMJ dysfunction   syndromes. Some may com-
plain about enlargement of the face and lack of pain. 
Clinical examination reveals asymmetrical growth 
over the ramus or mandibular angle, unilateral or bi-
lateral, which is more noticeable during occlusion.
Paraclinical diagnosis of MH by X-ray, ultra-
sound or computed tomography (CT) scan should 
be performed to exclude other soft tissue lesions. It 
is important to exclude the possible differential di-
agnosis, such as parotid tumors, lymphangiomas, li-
pomas, benign or malignant muscle tumors and an-
gio tumors. Many authors have described a connec-
tion between the square shape of the cross-section of 
mandibular muscles and facial morphology. Another 
results is that muscles are larger when patients have 
“shorter” in frontal facial height and decreased goni-
al angle. There is often a connection between form 
and function but it is not clear whether genetically 
determined facial morphology dictates the power of 
the muscles or powerful muscles influence the facial 
form (4,5,6,7).
Management of MH 
Clinically MH is treated only by esthetic com-
plaints. The different types of treatment start from 
combined muscle or bone removal to botulinum tox-
in injections. Surgical masseter resection and reduc-
tion of bone hyperostosis by means of intra- or extra-
oral access are conventional treatment methods af-
ter unsatisfactory result of occlusal correction, splint 
therapy, tranquilants, etc. Traditional surgical tech-
nique is performed under general anesthesia. The 
two techniques (intra- and extraoral) are actually a 
removal of vertical masseter fibers from the internal 
third of the muscle (9). Reduction osteoplasty could 
be performed as well. The remaining part of the mas-
seter should be attached to the mandibular peritone-
Mm. masseter have an important role in fa-
cial esthetics. Enlarged and hypertrophied muscles 
would change the contour of the face and could have 
negative esthetic impact. This could lead to potential 
asymmetry and/or square shape of the face, which is 
often considered a male feature. Masseter hypertro-
phy (МH) is a rare benign condition, characterized 
by asymptomatic enlargement of one or both mas-
seter muscles. The first description was by Legg in 
1880, who studied a 10-year-old girl with accompa-
nying idiopathic temporalis muscle hypertrophy (1). 
Frequency
MH is rarely observed, it is observed mainly in the 
second and third decade of life, and in some arti-
cle sources there is a lack of gender predisposition. 
Baek et al. (2), in own research based on 108 cases, 
report incidence of MH with prevalence in the pop-
ulation over 30 years of age, among which the re-
ported share of bilateral MH is 60% (3,4). It is noted 
in article sources that this is typical for certain eth-
nic groups. People of Asian ethnicity are more likely 
to have it and it is prevailing in men (5,6).
Еtiology 
Depending on etiology there are two types of 
muscle hypertrophy – congenital and acquired due 
to hyperfunction. Teixeira et al. (7), were the first to 
classify MH as congenital and acquired due to hy-
perfunction. There are some theoretical factors 
about the etiology of MH already described in litera-
ture but the exact reason remains unknown. The ac-
quired type is the most common of MH cases and bi-
lateral and symmetrical hypertrophy cases are pre-
vailing while unilateral MH could be seen in patients 
with unilateral mastication. In most cases MH is re-
lated to a bad habit like chewing on one side only due 
to loss of teeth or pain in some teeth. Other reasons 
are diseases and temporomandibular joint (TMJ) 
dysfunctions, bruxism, malocclusion, congenital ar-
teriovenous fistula or focal dystonia. Some authors 
say that emotional stress and bruxomania could lead 
to MH. Gurney (8)  describes a theory about hyper-
trophy, which explains that the asymmetrical mus-
cle size development has no relation to the patients’ 
activity.
Clinical Symptoms: 
Musculus masseter is one of the most impor-
tant masticatory muscles located to the side of ra-
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um to facilitate the healing period. The choice of ex-
ternal or internal incision is not related to cosmet-
ic or functional results, or the surgeon’s experience. 
In the beginning external access was more popular 
because of the better visualization. The procedure 
started with submandibular Risdon’s incision. Un-
like surgical excision of muscle tissue that decreases 
cell tissue volume, botulinum toxin type A decreas-
es the volume temporarily. Gourney, who performed 
it in 1947, is considered to be the founder of excision. 
It includes a submandibular incision and removal of 
between 1/3 and 3/4 of the muscular tissue – from 
the aponeurosa to the mandibular border. Removal 
of tissue by a triangular cut was performed by Mar-
tenson on a patient with a history of bruxism with 
unilateral hypertrophy (10). In 1977, Beckers surgi-
cally treated 17 patients using intraoral access and re-
moval of the internal part of the masseter. The inter-
nal muscle group is divided from the hypertrophi-
cal masseter by entrance in the zygomatic arch un-
til reaching the lower entrance towards mandibular 
angle. This approach avoids scarring and facial nerve 
damage (11). Another technique is the removal of 
bone convexity from the mandibular angle without 
muscle removal. Complications from masseter re-
moval include hematoma formations, facial nerve in-
juries, infections, trismus and general anesthesia is-
sues (12).
Application of Botulinum Toxin Type A (BTA) 
The first reports of BTA application of part of 
the MH treatment date back to 1994. A major part 
of the studies were performed in Asia (13,14,15,16). 
The efficiency of BTA injections in reducing volume 
of muscle tissue has been proven by ultrasound, elec-
tromyography and 3D scan as well as patient check-
ups. The negative part of the BTA therapy is the rel-
atively short effect and it disappears after 6 months 
(17). Although the BTA technique has shown good 
results, toxin dosage and place of injection in non-
Asian population is still poorly examined. The BTA 
protein is one of the seven immunologically divided 
neurotoxins produced by the anaerobic microorgan-
ism Clostridium Botulinum responsible for the clini-
cal infection called botulism. Local injection of very 
small amount of the toxin in the muscles produces 
local paralysis and separate muscles could be selec-
tively weakened with atrophy as a consequence. The 
toxin prevents acetylcholine production from the 
presynaptic vesicles, which causes presynaptic mus-
cle blockage. This method is a very effective alterna-
tive of the conventional surgical method and the pa-
tients do not suffer side effects. Side effects of BTA in-
jection therapy could be due to deep or wrongly ap-
plied injections, temporary paralysis of the nearby 
muscles but they disappear within 2 to 4 weeks. Pos-
sible reactions after treatment are moderate swelling, 
fever and pain. If the dose is too high muscle weak-
ness could appear and last up to 2 weeks. This kind 
of treatment provides doctors with a conservative 
nonsurgical therapy. There are 5 types of BTA avail-
able on the market: onabotulinum toxin А (BOTOX, 
Allergan Inc., Irvine, СА, САЩ), abotulinum toxin 
А (Dysport, Ipsen Limited, Wrexham, UK), BTXA 
(Prosigne, Lanzhou Institute, China), incobutinum 
toxin А (Xeomin, Mers Pharmaceuticals, Franfurkt 
AM Main, Germany), and Neuronox (Medytox Inc., 
Cheonwon-gun, South Corea) (18,19). In literature 
some authors try to achieve muscle atrophy by sec-
ondary application of the toxin following patient re-
quests but others recommend monthly applications 
of the toxin until suppressing muscle activity with 
frequent additional doses to stop the recovery of the 
muscle force by more than 30%. In regard to the areas 
of injection there is a tendency to establish a safe area 
zone after careful clinical examination. This area is 
relatively small and includes the region from the an-
gulus oris to the ear. The frontal end of the masseter 
muscles are palpable after occlusion. Radiofrequency 
electrocoagulation is a procedure that uses alterna-
tive source of energy causing ionic movement lead-
ing to tissue coagulation (60 – 80 0C) for protein de-
naturation. Although this is a relatively new proce-
dure for treating MH, this technique has been used 
in medical purposes as an alternative carcinoma 
treatment. In the end it causes focal necrosis of the 
masseter muscle, without negative effects, far from 
the place electricity is applied. The method is poor-
ly studied and documented so that the procedure is 
a possibility in treating MH but the long-term effects 
should be examined additionally (20,21,22,23).
CONCLUSION 
Despite the low MH incidence in Caucasians, 
dentists could benefit from the availability of an al-
ternative treatment in mild or moderate MH. The 
main purpose in the dental field is improving facial 
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esthetics and reducing masticatory forces. Patients 
want triangular or heart shaped faces, because of the 
delicate look. Also nowadays treatment methods try 
to establish triangular shape that prevails in youth, 
BTA treatment is a simple technique that could be 
successful and shows satisfactory results. According 
to data there is improvement in 100% of the brux-
ism patients but further researches are necessary. Re-
stricting the smile even with safe area injection is a 
must inform issue. In extreme cases with MH with 
facial deformities surgical techniques are indicated. 
In long term further randomized clinical trials about 
BTA usage and radiofrequency electrocoagulation 
should be performed. 
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